financetom
Business
financetom
/
Business
/
LandBridge Q3 revenue misses estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
LandBridge Q3 revenue misses estimates
Nov 12, 2025 2:29 PM

Overview

* LandBridge ( LB ) Q3 revenue grows 78% yr/yr but misses analyst expectations

* Adjusted EBITDA for Q3 rises 79% yr/yr but misses analyst estimates

* Company acquired about 37,500 acres, expanding holdings to over 300,000 surface acres

Outlook

* Company reaffirms FY 2025 Adjusted EBITDA between $165 mln and $175 mln

Result Drivers

* ACQUISITIONS - Acquisition of 37,500 acres expanded holdings and enhanced ability to meet demand for produced water handling and alternative energy development

* DIVERSIFIED REVENUE STREAMS - Revenue growth supported by increases in surface use royalties and oil and gas royalties

* ASSET-LIGHT MODEL - High margins and efficient capital use attributed to asset-light business model

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $50.80 $51.81

Revenue mln mln (6

Analysts

)

Q3 Net $20.30

Income mln

Q3 Miss $44.90 $46.44

Adjusted mln mln (6

EBITDA Analysts

)

Q3 88%

Adjusted

EBITDA

Margin

Q3 Free $33.70

Cash mln

Flow

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the oil & gas exploration and production peer group is "buy"

* Wall Street's median 12-month price target for LandBridge Co LLC ( LB ) is $70.50, about 15.6% below its November 12 closing price of $81.51

* The stock recently traded at 44 times the next 12-month earnings vs. a P/E of 29 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Why Branded Footwear Retailer Genesco's Shares Are Tumbling Today
Why Branded Footwear Retailer Genesco's Shares Are Tumbling Today
Mar 8, 2024
Genesco Inc shares are plummeting after reporting fourth-quarter FY24 sales growth of 2% year-on-year to $738.95 million, beating the analyst consensus estimate of $705.66 million. Excluding the 14th week, sales would have decreased 2% for the fourth quarter of fiscal 2024. Total comparable sales declined 4%. Overall sales dropped 2% at Journeys, grew 6% at Schuh, up 9% at Johnston & Murphy,...
Regenxbio Insider Sold Shares Worth $365,220, According to a Recent SEC Filing
Regenxbio Insider Sold Shares Worth $365,220, According to a Recent SEC Filing
Mar 8, 2024
08:11 AM EST, 03/08/2024 (MT Newswires) -- Steve Pakola, Chief Medical Officer, on March 05, 2024, sold 12,878 shares in Regenxbio ( RGNX ) for $365,220. Following the Form 4 filing with the SEC, Pakola has control over a total of 107,192 shares of the company, with 107,192 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1590877/000156218024002430/xslF345X03/primarydocument.xml Price: 23.69, Change: +0.46, Percent Change:...
Ani Pharmaceuticals Insider Sold Shares Worth $2,630,864, According to a Recent SEC Filing
Ani Pharmaceuticals Insider Sold Shares Worth $2,630,864, According to a Recent SEC Filing
Mar 8, 2024
08:09 AM EST, 03/08/2024 (MT Newswires) -- Muthusamy Shanmugam, Director, HEAD OF R&D, COO-NOVITIUM OPS, around March 05, 2024, sold 40,000 shares in Ani Pharmaceuticals ( ANIP ) for $2,630,864. Following the Form 4 filing with the SEC, Shanmugam has control over a total of 916,272 shares of the company, with 68,652 shares held directly and 847,620 shares controlled indirectly....
--B. Riley Trims FuelCell Energy's PT to $2 From $2.50 After Fiscal Q1 Miss on Lower-Than-Expected Service Revenue, Keeps Neutral Rating
--B. Riley Trims FuelCell Energy's PT to $2 From $2.50 After Fiscal Q1 Miss on Lower-Than-Expected Service Revenue, Keeps Neutral Rating
Mar 8, 2024
08:11 AM EST, 03/08/2024 (MT Newswires) -- Price: 1.14, Change: +0.02, Percent Change: +2.25 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved